Meningioma Survivor Story | Nick Stump | Ivy Brain Tumor Center

1 Views
administrator
administrator
07/02/23

In 2015, Nick Stump was exploring young adulthood like any other 23-year-old college graduate. Nick had recently received his bachelor’s degree from Northern Arizona University and was serving as a dedicated speech and debate coach when he started experiencing extreme headaches accompanied by nausea and vomiting. Hear more about Nick's story as a meningioma survivor.

-------------------------------------------------------------------------------------------------------------------------------
The Ivy Brain Tumor Center (https://www.ivybraintumorcenter.org/) at Barrow Neurological Institute in Phoenix, AZ, is a non-profit translational research program that employs a bold, early-phase clinical trials strategy to identify new treatments for aggressive brain tumors, including glioblastoma. The Ivy Center’s Phase 0 clinical trials program is the largest of its kind in the world. It enables personalized care in a fraction of the time and cost associated with traditional drug development. In addition, unlike conventional clinical trials focusing on single drugs, its accelerated trials program tests therapeutic combinations matched to individual patients.

How Ivy Phase 0 Clinical Trials Work: https://youtu.be/IE3U6mtwQCc
Benefits of Ivy Phase 0: https://youtu.be/Ks9TX5eVvpc

Curious if you or a loved one may be eligible for one of our clinical trials? Submit a free trial screening request today at
https://www.ivybraintumorcente....r.org/trialeligibili or call 602-406-8605.

Active Clinical Trials: https://www.ivybraintumorcente....r.org/phase-0-clinic
Clinical Trial Eligibility: https://www.ivybraintumorcente....r.org/trialeligibili
Learn more about Ivy Brain Tumor Center: https://www.ivybraintumorcenter.org/
Learn more about Barrow Neurological Institute: https://www.barrowneuro.org/
Donate to Brain Tumor Research: https://giveto.supportbarrow.org/braincancer

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next